<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011009'>Acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (AEL) is a rare type of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) for which diagnostic criteria have been refined in the 2008 World Health Organization (WHO) classification of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The relationship of AEL to <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) and to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC) is not clearly defined </plain></SENT>
<SENT sid="2" pm="."><plain>We conducted a retrospective, multi-institutional study of patients with AEL and compared them with patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC with <z:hpo ids='HP_0012132'>erythroid hyperplasia</z:hpo> (&gt; or = 50% erythroid cells) </plain></SENT>
<SENT sid="3" pm="."><plain>Among a total of 124 patients with AEL, 32% had a history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0011010'>chronic</z:hpo> cytopenia, 32% had therapy-related disease, and 35% had de novo disease </plain></SENT>
<SENT sid="4" pm="."><plain>Sixty-four percent of patients had unfavorable <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> risk-group karyotypes </plain></SENT>
<SENT sid="5" pm="."><plain>FLT3 and <z:mp ids='MP_0011356'>RAS</z:mp> mutations were infrequent, occurring in 6% and 2%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>The median overall survival (OS) of <z:hpo ids='HP_0000001'>all</z:hpo> AEL patients was 8 months, comparable with that of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>-MRC with <z:hpo ids='HP_0012132'>erythroid hyperplasia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The OS was related to cytogenetic risk group, but not blast count or morphologic <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings suggest that AEL is in the continuum of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0012132'>erythroid hyperplasia</z:hpo>, where karyotype rather than an arbitrary blast cutoff represents the most important prognostic factor </plain></SENT>
</text></document>